BioCryst Pharmaceuticals, Inc. (BCRX)
7.63
-0.61
(-7.40%)
USD |
NASDAQ |
Nov 05, 16:00
7.51
-0.12
(-1.57%)
After-Hours: 06:53
BioCryst Pharmaceuticals SG&A Expense (TTM) : 245.09M for Sept. 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 245.09M |
| June 30, 2026 | 328.11M |
| March 31, 2026 | 360.73M |
| December 31, 2025 | 348.65M |
| September 30, 2025 | 333.34M |
| June 30, 2025 | 315.41M |
| March 31, 2025 | 289.24M |
| December 31, 2024 | 266.13M |
| September 30, 2024 | 250.04M |
| June 30, 2024 | 235.61M |
| March 31, 2024 | 225.39M |
| December 31, 2023 | 213.89M |
| September 30, 2023 | 199.66M |
| June 30, 2023 | 185.94M |
| March 31, 2023 | 172.96M |
| December 31, 2022 | 159.37M |
| September 30, 2022 | 144.60M |
| June 30, 2022 | 142.68M |
| March 31, 2022 | 130.99M |
| December 31, 2021 | 118.82M |
| September 30, 2021 | 104.42M |
| June 30, 2021 | 86.62M |
| March 31, 2021 | 74.18M |
| December 31, 2020 | 67.93M |
| September 30, 2020 | 57.43M |
| Date | Value |
|---|---|
| June 30, 2020 | 51.97M |
| March 31, 2020 | 46.75M |
| December 31, 2019 | 37.12M |
| September 30, 2019 | 31.12M |
| June 30, 2019 | 27.31M |
| March 31, 2019 | 28.14M |
| December 31, 2018 | 29.51M |
| September 30, 2018 | 29.72M |
| June 30, 2018 | 25.14M |
| March 31, 2018 | 18.48M |
| December 31, 2017 | 13.93M |
| September 30, 2017 | 11.80M |
| June 30, 2017 | 11.21M |
| March 31, 2017 | 11.10M |
| December 31, 2016 | 11.25M |
| September 30, 2016 | 8.692M |
| June 30, 2016 | 8.667M |
| March 31, 2016 | 9.477M |
| December 31, 2015 | 10.33M |
| September 30, 2015 | 12.37M |
| June 30, 2015 | 11.46M |
| March 31, 2015 | 9.934M |
| December 31, 2014 | 7.461M |
| September 30, 2014 | 6.683M |
| June 30, 2014 | 6.208M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Amgen, Inc. | 5.299B |
| Halozyme Therapeutics, Inc. | 238.00M |
| Neurocrine Biosciences, Inc. | 1.06B |
| Agenus, Inc. | 38.48M |
| Anika Therapeutics, Inc. | 52.67M |